Home LiteratureArticle Details
PMID: 12379516 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases.

Annals of the rheumatic diseases ·Vol. 61 ·No. 11 ·2002-11-00 ·Pages 960-7

Hallegua DS, Weisman MH

Abstract

To review publications relating to the blocking of interleukin 1 (IL1) as a strategy for treating human disease, ranging from rheumatoid arthritis (RA) to Alzheimer's disease. The National Library of Medicine's PubMed database was searched for articles about pharmaceutical agents that reduce the biological actions of IL1. Fish oils and corticosteroids were identified as non-selective pharmacological interventions that reduce the activity of IL1, whereas a recombinant human IL1 receptor antagonist (anakinra) and a soluble recombinant type I IL1 receptor act selectively. To date, anakinra is the only selective intervention that has been shown in controlled clinical trials to be effective and well tolerated in the treatment of a specific human disorder, RA. In controlled clinical trials, anakinra provided significant clinical improvement and slowed radiographic disease progression in patients with active RA. Moreover, addition of anakinra to existing methotrexate treatment significantly reduced signs and symptoms of active disease. The clinical use of anakinra has been demonstrated in the management of RA, but blocking of IL1 in other human disorders, as well as the safety of the use of these blocking agents in chronic diseases, still needs to be defined by controlled clinical investigations.

MeSH Terms
Animals Antirheumatic Agents/therapeutic use Arthritis, Rheumatoid/drug therapy Disease Models, Animal Humans Interleukin 1 Receptor Antagonist Protein Interleukin-1/physiology Receptors, Interleukin-1/antagonists & inhibitors Recombinant Proteins/therapeutic use Sialoglycoproteins/therapeutic use
Chemicals
Antirheumatic Agents IL1RN protein, human Interleukin 1 Receptor Antagonist Protein Interleukin-1 Receptors, Interleukin-1 Recombinant Proteins Sialoglycoproteins
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Hallegua D S
Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA 90048, USA.
Weisman M H
References (57)
57 references, click to expand
  1. The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor.
    J Exp Med. 1994 Feb 1;179(2):739-43 PMID: 8294881
  2. Interferon blocks interleukin 1-induced prostaglandin release from human peripheral monocytes.
    J Immunol. 1987 May 1;138(9):2857-63 PMID: 3106491
  3. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.
    Crit Care Med. 1994 Jan;22(1):12-21 PMID: 8124953
  4. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
    JAMA. 1994 Jun 15;271(23):1836-43 PMID: 8196140
  5. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis.
    J Clin Invest. 1994 Jul;94(1):449-53 PMID: 8040288
  6. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease.
    Blood. 1994 Aug 15;84(4):1342-8 PMID: 8049450
  7. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10.
    J Immunol. 1995 Feb 1;154(3):1432-9 PMID: 7822808
  8. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses.
    J Immunol. 1995 May 15;154(10):5492-9 PMID: 7730651
  9. Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications.
    Arthritis Rheum. 1995 May;38(5):642-8 PMID: 7748221
  10. Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock.
    Shock. 1995 Apr;3(4):235-51 PMID: 7600191
  11. Microglial interleukin-1 alpha expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution.
    Neuropathol Appl Neurobiol. 1995 Aug;21(4):290-301 PMID: 7494597
  12. Biologic basis for interleukin-1 in disease.
    Blood. 1996 Mar 15;87(6):2095-147 PMID: 8630372
  13. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group.
    Arthritis Rheum. 1996 Jul;39(7):1092-101 PMID: 8670316
  14. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin.
    Blood. 1996 Oct 1;88(7):2465-72 PMID: 8839837
  15. Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium.
    Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):1061-6 PMID: 8887608
  16. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
    N Engl J Med. 1997 Oct 9;337(15):1029-35 PMID: 9321530
  17. Constitutive intra-articular expression of human IL-1 beta following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis.
    J Immunol. 1997 Oct 1;159(7):3604-12 PMID: 9317160
  18. The mechanism of action of methotrexate.
    Rheum Dis Clin North Am. 1997 Nov;23(4):739-55 PMID: 9361153
  19. In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes.
    J Rheumatol. 1998 Apr;25(4):753-62 PMID: 9558181
  20. Interleukin-1 receptor antagonist: role in biology.
    Annu Rev Immunol. 1998;16:27-55 PMID: 9597123
  21. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis.
    Rheum Dis Clin North Am. 1998 Aug;24(3):629-39 PMID: 9710891
  22. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.
    Arthritis Rheum. 1998 Dec;41(12):2196-204 PMID: 9870876
  23. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
    N Engl J Med. 1999 Jan 28;340(4):253-9 PMID: 9920948
  24. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
    Ann Intern Med. 1999 Mar 16;130(6):478-86 PMID: 10075615
  25. Infliximab for the treatment of fistulas in patients with Crohn's disease.
    N Engl J Med. 1999 May 6;340(18):1398-405 PMID: 10228190
  26. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
    Gastroenterology. 1999 Oct;117(4):761-9 PMID: 10500056
  27. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
    Crit Care Med. 1997 Jul;25(7):1115-24 PMID: 9233735
  28. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
    Lancet. 1999 Dec 4;354(9194):1932-9 PMID: 10622295
  29. The role of interleukin-1 beta in the pathogenesis of multiple myeloma.
    Hematol Oncol Clin North Am. 1999 Dec;13(6):1117-25 PMID: 10626139
  30. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene.
    J Exp Med. 2000 Jan 17;191(2):303-12 PMID: 10637274
  31. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice.
    J Exp Med. 2000 Jan 17;191(2):313-20 PMID: 10637275
  32. Cytokine blockade as a new strategy to treat rheumatoid arthritis: inhibition of tumor necrosis factor.
    Arch Intern Med. 2000 Feb 28;160(4):437-44 PMID: 10695684
  33. Association of interleukin-1 gene polymorphisms with Alzheimer's disease.
    Ann Neurol. 2000 Mar;47(3):365-8 PMID: 10716257
  34. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.
    Arthritis Rheum. 2000 May;43(5):1001-9 PMID: 10817552
  35. The pervasiveness of interleukin-1 in alzheimer pathogenesis: a role for specific polymorphisms in disease risk.
    Exp Gerontol. 2000 Jul;35(4):481-7 PMID: 10959036
  36. Tumor necrosis factor: biology and therapeutic inhibitors.
    Gastroenterology. 2000 Oct;119(4):1148-57 PMID: 11040201
  37. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
    N Engl J Med. 2000 Nov 30;343(22):1586-93 PMID: 11096165
  38. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
    N Engl J Med. 2000 Nov 30;343(22):1594-602 PMID: 11096166
  39. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis.
    Semin Arthritis Rheum. 2001 Apr;30(5 Suppl 2):17-20 PMID: 11357167
  40. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis.
    Lancet. 1988 Sep 24;2(8613):706-9 PMID: 2901567
  41. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells.
    N Engl J Med. 1989 Feb 2;320(5):265-71 PMID: 2783477
  42. Autocrine stimulation of interleukin 1 alpha in the growth of adult human T-cell leukemia cells.
    Cancer Res. 1989 Mar 1;49(5):1143-7 PMID: 2783884
  43. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever.
    J Infect Dis. 1990 Jan;161(1):79-84 PMID: 2295861
  44. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects.
    Arthritis Rheum. 1990 Jun;33(6):810-20 PMID: 2363736
  45. Cytokines in symptomatic asthma airways.
    J Allergy Clin Immunol. 1992 May;89(5):958-67 PMID: 1374772
  46. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis.
    Gastroenterology. 1992 Jul;103(1):65-71 PMID: 1535326
  47. Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue.
    Ann Rheum Dis. 1992 Jun;51(6):731-4 PMID: 1616355
  48. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans.
    Cytokine. 1992 Sep;4(5):353-60 PMID: 1420996
  49. Interleukin-1 beta and tumor necrosis factor-alpha release in normal and diseased human infrarenal aortas.
    J Vasc Surg. 1992 Nov;16(5):784-9 PMID: 1433667
  50. The role of interleukin-1 in disease.
    N Engl J Med. 1993 Jan 14;328(2):106-13 PMID: 8439348
  51. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.
    Arthritis Rheum. 1993 Jun;36(6):729-40 PMID: 8507213
  52. Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans.
    Blood. 1993 Nov 15;82(10):2985-90 PMID: 8219190
  53. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.
    J Rheumatol. 2001 Jun;28(6):1238-44 PMID: 11409115
  54. Pharmacological therapy of osteoarthritis.
    Best Pract Res Clin Rheumatol. 2001 Oct;15(4):583-93 PMID: 11567541
  55. Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes.
    J Rheumatol. 2001 Dec;28(12):2692-9 PMID: 11764219
  56. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Arthritis Rheum. 2002 Mar;46(3):614-24 PMID: 11920396
  57. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment.
    Clin Exp Immunol. 1994 Feb;95(2):237-43 PMID: 8306498
Article Info
Journal
Annals of the rheumatic diseases
Abbr.
Ann Rheum Dis
ISSN
0003-4967
DOI
10.1136/ard.61.11.960
Published
2002-11-00
Pages
960-7
Language
English
Region
England
NLM ID
0372355
PMCID
PMC1753951
Subset
IM
External Links
PubMed source DOI: 10.1136/ard.61.11.960 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2